APA (7th ed.) Citation

E, M., HM, A., R, E., AM, A., & GE, B. (2026). Reimagining GSK-3β Therapeutics in Alzheimer's Disease: From Inhibition to Activity Normalization and Targeted Degradation. Journal of molecular neuroscience : MN, 76(2), . https://doi.org/10.1007/s12031-026-02518-9

Chicago Style (17th ed.) Citation

E, Manni, Al-Kuraishy HM, Eisawy R, Abdelaziz AM, and Batiha GE. "Reimagining GSK-3β Therapeutics in Alzheimer's Disease: From Inhibition to Activity Normalization and Targeted Degradation." Journal of Molecular Neuroscience : MN 76, no. 2 (2026). https://doi.org/10.1007/s12031-026-02518-9.

MLA (9th ed.) Citation

E, Manni, et al. "Reimagining GSK-3β Therapeutics in Alzheimer's Disease: From Inhibition to Activity Normalization and Targeted Degradation." Journal of Molecular Neuroscience : MN, vol. 76, no. 2, 2026, https://doi.org/10.1007/s12031-026-02518-9.